• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 21Zotepine vs. FGA (Acute treatment)

Outcome or SubgroupkTotal NStatistical MethodEffect [95% CI]
7.1 Global state: 2. Not improved to a clinically important degree (CGI?) (short-term)3262RR (M-H, Fixed, 95% CI)0.73 [0.60, 0.88]
 7.1.1 vs HAL2156RR (M-H, Fixed, 95% CI)0.84 [0.70, 1.01]
 7.1.2 vs other FGA1106RR (M-H, Fixed, 95% CI)0.48 [0.29, 0.81]
7.2 Mental state: 1. BPRS total (endpoint, high=poor) (short-term)3200MD (IV, Fixed, 95% CI)−6.50 [−11.28, −1.73]
 7.2.1 vs HAL295MD (IV, Fixed, 95% CI)−3.80 [−10.55, 2.96]
 7.2.2 vs other FGA1105MD (IV, Fixed, 95% CI)−9.20 [−15.94, −2.46]
7.3 Leaving the study early: 1. Any reason (short-to-medium-term)5427RR (M-H, Fixed, 95% CI)0.84 [0.70, 1.02]
 7.3.1 vs HAL (short-term)2156RR (M-H, Fixed, 95% CI)0.82 [0.57, 1.16]
 7.3.2 vs HAL (medium-term)1125RR (M-H, Fixed, 95% CI)0.98 [0.74, 1.30]
 7.3.3 vs other FGA (short-term)2146RR (M-H, Fixed, 95% CI)0.73 [0.50, 1.06]
7.4 AE: 1. Metabolic side effects - weight change (short-term)1105MD (IV, Fixed, 95% CI)−1.30 [−6.26, 3.66]
 7.4.1 vs HAL00MD (IV, Fixed, 95% CI)Not estimable
 7.4.2 vs other FGA1105MD (IV, Fixed, 95% CI)−1.30 [−6.26, 3.66]
7.5 AE: 1. Metabolic side effects - weight change from baseline (kg) (medium-term)1125MD (IV, Fixed, 95% CI)Not estimable
 7.5.1 vs HAL1125MD (IV, Fixed, 95% CI)Not estimable
7.6 AE: 1. Metabolic side effects - treatment emergent (short-term)4302RR (M-H, Fixed, 95% CI)1.06 [0.84, 1.33]
 7.6.1 vs HAL: liver function abnormalities3196RR (M-H, Fixed, 95% CI)1.17 [0.89, 1.55]
 7.6.2 vs other FGA: liver function abnormalities1106RR (M-H, Fixed, 95% CI)0.85 [0.56, 1.29]
7.7 AE: 2. Neurologic side effects - Use of anticholinergic medication (short-term)3221RR (M-H, Fixed, 95% CI)0.65 [0.54, 0.77]
 7.7.1 vs HAL3221RR (M-H, Fixed, 95% CI)0.65 [0.54, 0.77]
7.8 AE: 2. Neurologic side effects (treatment-emergent) (short-term)
 7.8.1 vs HAL: any extrapyramidal event1125RR (M-H, Fixed, 95% CI)0.28 [0.08, 0.94]
 7.8.2 vs HAL: tremor4324RR (M-H, Fixed, 95% CI)0.60 [0.39, 0.94]
 7.8.3 vs HAL: akathisia3196RR (M-H, Fixed, 95% CI)0.65 [0.48, 0.88]
 7.8.4 vs HAL: asthenia1125RR (M-H, Fixed, 95% CI)1.68 [0.50, 5.66]
 7.8.5 vs HAL: dystonia270RR (M-H, Fixed, 95% CI)0.47 [0.24, 0.93]
 7.8.6 vs HAL: dyskinesia2251RR (M-H, Fixed, 95% CI)0.77 [0.54, 1.10]
 7.8.7 vs HAL: rigidity270RR (M-H, Fixed, 95% CI)0.50 [0.30, 0.83]
 7.8.8 vs other FGA: akathisia1106RR (M-H, Fixed, 95% CI)0.77 [0.49, 1.20]
 7.8.9 vs other FGA: asthenia1106RR (M-H, Fixed, 95% CI)0.86 [0.58, 1.27]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.